Biophotonic compositions, methods, and kits for pain relief

Patent metadata

Field	Value
Publication number	US-2020376121-A1
Application number	US-201716333794-A
Country	US
Kind code	A1
Filing date	Sep 22, 2017
Priority date	Sep 23, 2016
Publication date	Dec 3, 2020
Grant date	—

Abstract

The present document describes methods and uses of compositions which comprise at least one photoactivator or chromophore in association with a pharmacologically acceptable carrier for use in reducing pain that is associated with a medical condition in a subject.

First claim

1 . A method for reducing pain associated with a medical condition in a subject, comprising:
a) topically applying a composition comprising at least one photoactivator and a pharmaceutically acceptable carrier; and b) exposing said composition to actinic light to cause activation of the composition, wherein the pain associated with the medical condition is treated non-systemically.

2 . The method according to claim 1 , wherein the pain does not originate from a stimulus in an orofacial region.

3 . The method according to claim 1 , wherein the reduction of pain is not dependent on the treatment of the underlying medical condition.

4 . The method according claim 1 , wherein the composition is a biophotonic composition.

5 . The method according claim 1 , wherein the photoactivator is selected from the group consisting of a xanthene derivative dye, an azo dye, a biological stain, and a carotenoid.

6 . The method according to claim 5 , wherein the at least one photoactivator is selected from the group consisting of eosin, erythrosine, and Saffron red powder.

7 . (canceled)

8 . The method according to claim 6 , wherein the at least one photoactivator is eosin Y.

9 . The method according to claim 6 , wherein the at least one photoactivator is erythrosine B.

10 . The method according to claim 1 , wherein the at least one photoactivator is present in an amount of at least about 0.02% by weight of the composition.

11 .- 34 . (canceled)

35 . The method according to claim 1 , wherein the composition further comprises at least one healing factor.

36 . The method according to claim 35 , wherein the healing factor is selected from the group consisting of hyaluronic acid, glucosamine, and allantoin.

37 .- 51 . (canceled)

52 . The method according to claim 35 , wherein the composition further comprises at least one salt selected from the group consisting of:
one or more bicarbonate salts selected from the group consisting of ammonium bicarbonate, caesium bicarbonate, potassium bicarbonate, sodium bicarbonate, choline bicarbonate, aminoguanidine bicarbonate, tetraethyl ammonium bicarbonate, sodium bicarbonate, and potassium bicarbonate; one or more carbonate salts selected from the group consisting of barium carbonate, beryllium carbonate, caesium carbonate, calcium carbonate, cobalt (II) carbonate, copper (II) carbonate, lithium carbonate, magnesium carbonate, nickel (II) carbonate, potassium carbonate, sodium carbonate, zinc carbonate, sodium carbonate, calcium carbonate, and potassium bicarbonate; and a combination of the foregoing salts.

53 .- 56 . (canceled)

57 . The method according to claim 1 , wherein the pain is acute or chronic pain.

58 . The method according to claim 57 , wherein the chronic pain is nociceptive pain or neuropathic pain.

59 . The method according to claim 1 , wherein the pain is selected from the group consisting of widespread pain, localized pain, nociceptive pain, inflammatory pain, peripheral neuropathic pain, peripheral neurogenic pain, peripheral neuralgia, low back pain, postoperative pain, visceral pain, and pelvic pain; allodynia; anesthesia dolorosa; causalgia; dysesthesia; fibromyalgia; hyperalgesia; hyperesthesia; ischemic pain; sciatic pain; pain associated with cystitis including, but not limited to, interstitial cystitis; pain associated with multiple sclerosis; pain associated with arthritis; pain associated with osteoarthritis; pain associated with rheumatoid arthritis; pain associated with chronic wounds; pain associated with burns; and pain associated with cancer.

60 .- 65 . (canceled)

66 . The method according to claim 1 , wherein the pain is associated with postoperative care.

67 . The method according to claim 1 , wherein said composition is exposed to actinic light for at least one treatment period of from about 1 second to about 9 minutes per cm 2 of an area to be treated, the actinic light having a wavelength between about 400 nm and about 700 nm, the illumination thereof being in continuous motion over the area to be treated.

68 .- 74 . (canceled)

75 . The method according to claim 1 , wherein said composition is exposed to at least two treatment periods of actinic light wherein each treatment period is from about 1 minute to about 5 minutes per cm of an area to be treated, and wherein each treatment period is followed by a resting interval of from about 1 minute to about 5 minutes.

76 . (canceled)

77 . The method according claim 1 , further comprising:
a) topically applying the composition to the subject's area of pain; b) exposing the subject's area of pain to actinic light for a treatment period of from about 1 minute to about 10 minutes; c) removing the source of actinic light away from the subject's area of pain treated for a resting interval of from about 1 minute to about 5 minutes; d) exposing the subject's area of pain to actinic light for a second treatment period of from about 1 minute to about 10 minutes; and wherein the first exposure to actinic light activates the composition.

78 .- 91 . (canceled)

92 . A method of reducing pain associated with a medical condition in a subject, comprising:
a) identifying area of the pain; b) topically applying on the subject's areas of pain a composition comprising at least one photoactivator and a pharmaceutically acceptable carrier; and c) exposing the subject's area of pain to actinic light for a time sufficient to activate said composition.

93 .- 94 . (canceled)

Assignees

• Klox Tech Inc

Inventors

• Nikolis Andreas
• Romanelli Marco
• Loupis Nikolaos
• Piergallini Remigio
• Dini Valentina

Classifications

• A61K36/185

  Magnoliopsida (dicotyledons) · CPC title

• A61K31/352

  condensed with carbocyclic rings, e.g. methantheline  {(cannabinoids A61K31/658)} · CPC title

• A61K31/365

  Lactones · CPC title

• A61K31/728

  Hyaluronic acid · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title